Coaching Patients Saves Lives and Money

被引:13
作者
Byrnes, Joshua [1 ,2 ]
Elliott, Thomas [3 ]
Vale, Margarite J. [4 ]
Jelinek, Michael V. [4 ,5 ]
Scuffham, Paul [1 ,2 ]
机构
[1] Griffith Univ, Ctr Appl Hlth Econ, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Brisbane, Qld, Australia
[3] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[5] St Vincents Hosp, Dept Cardiol, Melbourne, Vic, Australia
关键词
Cardiovascular disease; Cost-benefit analysis; Disease management; Evidence-practice gaps; Health coaching; SECONDARY PREVENTION; DISEASE MANAGEMENT; VASCULAR-DISEASE; RANDOMIZED-TRIAL; CORONARY; METAANALYSIS; CARE; INHIBITORS;
D O I
10.1016/j.amjmed.2017.10.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The Coaching On Achieving Cardiovascular Health (COACH) Program has been proven to improve biomedical and lifestyle cardiovascular disease (CVD) risk factors. The objective of this study was to evaluate the long-term impact of The COACH Program on overall survival, hospital utilization, and costs from the perspective of a private health insurer (payor), in patients with CVD. METHODS: A prospective parallel-group case-control study design with controls randomly matched to patients based on propensity score. There were 512 participants with CVD engaged in a structured disease management program of 6 months duration (The COACH Program) who were matched to 512 patients with CVD who were allocated to the control group. The independent variables that estimated the propensity score were preprogram hospital admissions, age, and sex. The primary outcome was overall survival with secondary outcomes, including hospital utilization and cost incurred by the private health insurer. Mean followup was 6.35 years. Difference in overall survival between the 2 groups was estimated using a Cox proportional hazard ratio (HR) with difference in total cost estimated using a generalized linear model. RESULTS: The COACH Program achieved a significant reduction in overall mortality (HR 0.70; 95% confidence interval [CI], 0.53-0.93; P = .014). There was an apparent dose-response effect: those who received up to 3 coaching sessions had no decrease in mortality (HR 1.02; 95% CI, 0.69-1.49; P = .926); those who received 4 or more coaching sessions had a substantial decrease in mortality (HR 0.58; 95% CI, 0.42-0.81; P = .001). Total cost to the health insurer was substantially lower in the intervention group ($ 12,707 per person lower; P = .078). The reduction in total cost was significantly greater in those who received 4 or more sessions ($ 19,418 per person; P = .006) and in males ($ 18,947 per person; P = .029). CONCLUSIONS: Those enrolled in The COACH program achieved a statistically significant decrease in overall mortality compared with usual care at 6.35 years. A substantive reduction in hospital costs was also observed among those who received The COACH program compared with those who did not, particularly in those who received 4 or more sessions and in males. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:415 / +
页数:8
相关论文
共 25 条
[1]   Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia [J].
Banks, Emily ;
Crouch, Simon R. ;
Korda, Rosemary J. ;
Stavreski, Bill ;
Page, Karen ;
Thurber, Katherine A. ;
Grenfell, Robert .
MEDICAL JOURNAL OF AUSTRALIA, 2016, 204 (08) :320.e1-320.e8
[2]   Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non ST-Elevation Acute Coronary Syndrome [J].
Bavishi, Chirag ;
Panwar, Sadik ;
Messerli, Franz H. ;
Bangalore, Sripal .
AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (05) :809-817
[3]   Disease management in the American market [J].
Bodenheimer, T .
BRITISH MEDICAL JOURNAL, 2000, 320 (7234) :563-566
[4]   The impact of population-based disease management services for selected chronic conditions: the Costs to Australian Private Insurance - Coaching Health (CAPICHe) study protocol [J].
Byrnes, Joshua M. ;
Goldstein, Stan ;
Venator, Benjamin ;
Pollicino, Christine ;
Shu-Kay Ng ;
Veroff, David ;
Bennett, Christine ;
Scuffham, Paul A. .
BMC PUBLIC HEALTH, 2012, 12
[5]   Interpretation of the evidence for the efficacy and safety of statin therapy [J].
Collins, Rory ;
Reith, Christina ;
Emberson, Jonathan ;
Armitage, Jane ;
Baigent, Colin ;
Blackwell, Lisa ;
Blumenthal, Roger ;
Danesh, John ;
Smith, George Davey ;
DeMets, David ;
Evans, Stephen ;
Law, Malcolm ;
MacMahon, Stephen ;
Martin, Seth ;
Neal, Bruce ;
Poulter, Neil ;
Preiss, David ;
Ridker, Paul ;
Roberts, Ian ;
Rodgers, Anthony ;
Sandercock, Peter ;
Schulz, Kenneth ;
Sever, Peter ;
Simes, John ;
Smeeth, Liam ;
Wald, Nicholas ;
Yusuf, Salim ;
Peto, Richard .
LANCET, 2016, 388 (10059) :2532-2561
[6]  
Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
[7]   Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials [J].
Dagenais, Gilles R. ;
Pogue, Janice ;
Fox, Kim ;
Simoons, Marteen L. ;
Yusuf, Salim .
LANCET, 2006, 368 (9535) :581-588
[8]   Reducing risk in coronary artery disease. Are Australian patients in general practice achieving targets? The Coronary Artery Disease in general practice study (CADENCE) [J].
Driscoll, A. ;
Beltrame, J. ;
Beauchamp, A. ;
Morgan, C. ;
Weekes, A. ;
Tonkin, A. .
INTERNAL MEDICINE JOURNAL, 2013, 43 (05) :526-531
[9]   Evidence-based disease management [J].
Ellrodt, G ;
Cook, DJ ;
Lee, J ;
Cho, M ;
Hunt, D ;
Weingarten, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (20) :1687-1692
[10]   Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis [J].
Ettehad, Dena ;
Emdin, Connor A. ;
Kiran, Amit ;
Anderson, Simon G. ;
Callender, Thomas ;
Emberson, Jonathan ;
Chalmers, John ;
Rodgers, Anthony ;
Rahimi, Kazem .
LANCET, 2016, 387 (10022) :957-967